PROJECT

Projects

Summary of Investment Information

Project Number

46047

Company Name

EUROFARMA LABORATORIOS S/A

Date SPI Disclosed

Sep 12, 2022

Country

Brazil

Region

Latin America and the Caribbean

Projected Board Date

Jun 24, 2022

Environmental Category

B - Limited

Status

Active

Last Updated Date

Oct 29, 2022

Department

Regional Industry MAS LAC & EUR

Industry

other

Previous Events

Approved : Jun 24, 2022
Signed : Aug 30, 2022
Invested : Oct 25, 2022

Sector

other

Project Description

 The proposed investment entails an up to US$150 million A loan and an up to US$100 million B loan to Eurofarma Laboratórios S.A. (Eurofarma or the Company), a life science manufacturing company headquartered in Brazil with presence across Latin America. The proceeds will be used to fund i) the construction of a greenfield pharmaceutical manufacturing plant in Montes Claros, Brazil to produce oral solids and antibiotics; and (ii) the equipment needed to do the fill and finish of the Pfizer COVID-19 vaccine in Brazil (both investments together are defined as the “Project”).

Eurofarma was founded in Sao Paulo, southeast of Brazil, in 1972 as a family business and has grown rapidly to become a regional manufacturer of prescription drugs, generic drugs and medicine solutions to public and private hospitals.                                                  

Associated Advisory Engagement

                                    

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation